^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    WDR43 (WD Repeat Domain 43)

    i
    Other names: WDR43, WD Repeat Domain 43, UTP5, U3 Small Nucleolar RNA-Associated Protein 5 Homolog, WD Repeat-Containing Protein 43, KIAA0007, NET12, UTP5, Small Subunit (SSU) Processome Component, Homolog (Yeast), UTP5 Small Subunit (SSU) Processome Component Homolog
    7ms
    ALKBH1 drives tumorigenesis and drug resistance via tRNA decoding reprogramming and codon-biased translation. (PubMed, Cancer Discov)
    Targeting ALKBH1, particularly together with venetoclax, exhibited potent anti-leukemia efficacy in preclinical models with favorable safety profiles. Collectively, our findings elucidate ALKBH1's pivotal role in codon-biased translation and tumorigenesis, and propose a novel therapeutic strategy for cancer treatment.
    Journal
    |
    WDR43 (WD Repeat Domain 43)
    |
    Venclexta (venetoclax)
    1year
    Identification of narciclasine as a novel NRF2 inhibitor. (PubMed, Free Radic Res)
    Narciclasine suppressed the expression of NRF2 and NRF2 target genes, caused significant oxidative stress, and sensitized cisplatin-mediated apoptosis in A549 cells...Finally, we observed that administration of narciclasine significantly decreased the growth of A549 xenografts. Together, our results demonstrate that the inhibition of NRF2 by narciclasine is mediated by WDR43 and future studies are necessary to elucidate the exact mechanism how WDR43 mediates the inhibition of NRF2 by narciclasine.
    Journal
    |
    WDR43 (WD Repeat Domain 43) • WDR4 (WD Repeat Domain 4)
    |
    KEAP1 mutation • NFE2L2 mutation
    |
    cisplatin
    over1year
    WD repeat domain 43 as a new predictive indicator and its connection with tumor immune cell infiltration in pan-cancer. (PubMed, Medicine (Baltimore))
    We conducted a thorough investigation of the clinical features, phases of tumor development, immune infiltration, gene mutation, and functional enrichment analysis of WDR43 in various types of cancer. This research offers valuable insight into the significance and function of WDR43 in clinical therapy.
    Journal • Tumor mutational burden • Pan tumor • Immune cell
    |
    TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • WDR43 (WD Repeat Domain 43) • WDR4 (WD Repeat Domain 4)
    almost2years
    Comprehensive analysis identifies long non-coding RNA RNASEH1-AS1 as a potential prognostic biomarker and oncogenic target in hepatocellular carcinoma. (PubMed, Am J Cancer Res)
    Finally, mechanistic studies demonstrated that the stability of RNASEH1-AS1 could be regulated by DKC1 via their direct interaction. Taken together, RNASEH1-AS1 may serve as a potential prognostic and diagnostic biomarker and oncogenic lncRNA for HCC.
    Journal
    |
    PD-1 (Programmed cell death 1) • DKC1 (Dyskerin Pseudouridine Synthase 1) • WDR43 (WD Repeat Domain 43) • DDX10 (DEAD-Box Helicase 10) • EIF4A3 (Eukaryotic Translation Initiation Factor 4A3)
    2years
    Identification of common genes and pathways underlying imatinib and nilotinib treatment in CML: a Bioinformatics Study. (PubMed, Nucleosides Nucleotides Nucleic Acids)
    Moreover, 20 downregulated genes, YARS, AARS, SARS, GARS, CARS, IARS, RRP79, CEBPB, RRP12, UTP14A, PNO1, CCND1, DDX10, MYC, WDR43, CEBPG, DDIT3, VEGFA, PIM1 and TRIB3 were identified as hub genes. These genes have the potential to become target genes for diagnosis and therapy of CML patients.
    Journal
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • CCND1 (Cyclin D1) • PIM1 (Pim-1 Proto-Oncogene) • CYP3A5 (Cytochrome P450 Family 3 Subfamily A Member 5) • DDIT3 (DNA-damage-inducible transcript 3) • TRIB3 (Tribbles Pseudokinase 3) • WDR43 (WD Repeat Domain 43) • CPT1A (Carnitine Palmitoyltransferase 1A) • CYP1A1 (Cytochrome P450 Family 1 Subfamily A Member 1) • DDX10 (DEAD-Box Helicase 10) • FABP1 (Fatty Acid Binding Protein 1) • CITED2 (Cbp/P300 Interacting Transactivator With Glu/Asp Rich Carboxy-Terminal Domain 2)
    |
    imatinib • nilotinib
    over2years
    RRP9 and DDX21 as new biomarkers of colorectal cancer. (PubMed, Medicine (Baltimore))
    RRP9 and DDX21 are highly expressed in CRC. The higher the expression level of RRP9 and DDX21, the worse the prognosis.
    Journal
    |
    PLK1 (Polo Like Kinase 1) • IL17A (Interleukin 17A) • MELK (Maternal Embryonic Leucine Zipper Kinase) • DKC1 (Dyskerin Pseudouridine Synthase 1) • WDR43 (WD Repeat Domain 43) • MAD2L1 (Mitotic Arrest Deficient 2 Like 1) • RACGAP1 (Rac GTPase activating protein 1) • RFC4 (Replication Factor C Subunit 4) • TPX2 (TPX2 Microtubule Nucleation Factor) • UBE2C (Ubiquitin Conjugating Enzyme E2 C)
    3years
    The c-MYC-WDR43 signalling axis promotes chemoresistance and tumour growth in colorectal cancer by inhibiting p53 activity. (PubMed, Drug Resist Updat)
    Oxaliplatin chemoresistance is a major challenge in the clinical treatment of colorectal cancer (CRC), which is one of the most common malignancies worldwide...WDR43 enhances the ubiquitination of p53 by MDM2 through binding to RPL11, thereby reducing the stability of the p53 protein, which induces proliferation and chemoresistance of CRC cells. Thus, the overexpression of WDR43 promotes CRC progression, and could be a potential therapeutic target of chemoresistance in CRC.
    Journal
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • WDR43 (WD Repeat Domain 43) • RPL11 (Ribosomal Protein L11)
    |
    oxaliplatin
    over3years
    WD Repeat Domain 43 promotes malignant progression of non-small cell lung cancer by regulating CDK2. (PubMed, Int J Biochem Cell Biol)
    WDR43 can directly interact with cyclin-dependent kinase 2 and induce the expression of cyclin proteins. Our results suggest that WDR43 is a promising target of protein-protein interaction inhibitors for treatment of NSCLC.
    Journal
    |
    CDK2 (Cyclin-dependent kinase 2) • WDR43 (WD Repeat Domain 43)
    4years
    Expression profile of RNA binding protein in cervical cancer using bioinformatics approach. (PubMed, Cancer Cell Int)
    Our discovery showed that many RNA binding proteins involved in the progress of cervical cancer, which could probably serve as prognostic biomarkers and accelerate the discovery of treatment targets for CC patients.
    Journal
    |
    WDR43 (WD Repeat Domain 43)
    4years
    Two distinct mechanisms underlie estrogen-receptor-negative breast cancer susceptibility at the 2p23.2 locus. (PubMed, Eur J Hum Genet)
    Two SNPs (rs11680458 and rs1131880) in Regulatory Region 3, mapping to the seed region for miRNA-recognition sites in the 3' untranslated region of WDR43, showed allele-specific effects of ectopic expression of miR-376 on WDR43 expression levels. Taken together, our data suggest that risk of ER-negative breast cancer associated with the 2p23.2 locus is likely driven by a combinatorial effect on the regulation of WDR43 and PLB1.
    Journal
    |
    ER (Estrogen receptor) • WDR43 (WD Repeat Domain 43)
    |
    ER negative
    over4years
    WD40 repeat 43 mediates cell survival, proliferation, migration and invasion via vimentin in colorectal cancer. (PubMed, Cancer Cell Int)
    In conclusion, the role of WDR43 in the occurrence and development of CRC was investigated in the present study. WDR43 may serve as a valuable biomarker and provide new options for the diagnosis and treatment of colorectal cancer.
    Journal
    |
    VIM (Vimentin) • WDR43 (WD Repeat Domain 43)
    |
    VIM expression